Business Wire

AZ-AXWAY

30.11.2022 08:01:52 CET | Business Wire | Press release

Share
New survey reveals API strategies, concerns as enterprises look to securely free data for business growth

Axway (Euronext: AXW.PA), a leading provider of API management and integration software, today announced new data from its inaugural 2022 Open Everything Strategy Survey Report. Polling nearly 1,000 IT leaders, architects, and developers about their digital strategies and top concerns, the survey found nearly 40% of organizations are in the process of adopting a new hybrid approach for their IT infrastructure. The transformation comes as 68% of respondents cite their fears about API sprawl.

The survey data reflects responses from those engaged primarily in API development (893) and managed file transfer (MFT) services (102). Ensuring data security and controlling API sprawl were top concerns, with over two-thirds (68%) worrying about complexity due to sprawl and almost half (48%) of respondents ranking “increased security challenges” as their single greatest concern with API growth. Respondents again cited security as far and away the most important criteria when creating an API (30% among API respondents) and when setting up a new MFT service (48% among MFT respondents).

“Enterprises are in the thick of digital transformation and accompanying cloud and data migrations have made it possible to free up data so it can be exchanged, reused and remixed to fuel innovation and business growth. But that’s messy,” said Vince Padua, Chief Innovation and Technology Officer at Axway. “It brings complexity and security challenges that must be answered by using truly universal API management—that bridges the gap between API development and consumption and opens everything, lines of business and innovation, while building on and out from heritage infrastructure.”

The survey results indicate that budgets for API management have increased over the past two years and that security is top of mind as companies begin to unlock the full value of their data to create new digital experiences, markets and opportunities for revenue. Half of those surveyed reported modestly elevated API management budgets, with about 34% of respondents seeing increases up to 25%. Less than 20% of respondents saw budget decreases.

Drilling down further into security strategy and the impending skills gap

Digging deeper, the survey found that a significant majority, 59%, employ user authentication as a top strategy to secure APIs, and almost two-thirds of the API respondents (61%) said data encryption can help them personally feel their data is more secure. They also cited developing a more holistic approach to security as the number one strategy for protecting personal data.

When a member logs into our online channels or walks into one of our branches, we want to personalize their experience in real time. To achieve this, we targeted a high-performance API integration layer,” said Ravi Peru, Chief Information Officer at Community America Credit Union.

"When you have more than 50 products, handling integration in an agile way is very important," added Peru. "With Axway, we can interface with anything and move data between any internal systems we want. That would be really slow with point-to-point integration, but Axway makes it quick and easy."

Security factors into cloud strategy as well. Among the most significant challenges inhibiting cloud strategy, according to respondents, are:

  • 53% – Dealing with different security requirements for regional instances of cloud infra
  • 55% – Tracking and controlling the flow of personal data into and through the cloud

One of the most alarming, but not entirely surprising data points, deals with concerns about talent: 86% of API respondents fear an expertise gap in the coming years, where companies will not have the skilled software and IT infrastructure talent they need to innovate.

Click here to see the full report.

Survey Methodology

The 2022 Open Everything Strategy Survey was conducted between July 21 and August 16 of 2022 among two similar, but divided subsets of respondents: API development and MFT integration professionals. Axway engaged in direct email outreach among its contacts with opt-in email addresses, and received nearly 1,000 responses, including 893 from those in API development and 102 in MFT services, from various locations throughout the world.

About Axway

Axway enables enterprises to securely open everything by integrating and moving data across a complex world of new and old technologies. Axway’s API-driven B2B integration and MFT software, refined over 20 years, complements Axway Amplify, an open API management platform that makes APIs easier to discover and reuse across multiple teams, vendors, and cloud environments. Axway has helped over 11,000 businesses unlock the full value of their existing digital ecosystems to create brilliant experiences, innovate new services, and reach new markets. Learn more at axway.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221129006117/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release

Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release

Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release

Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release

− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex

Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release

Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye